RGLS 4326

Drug Profile

RGLS 4326

Alternative Names: RGLS-4326

Latest Information Update: 26 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regulus Therapeutics
  • Class Antisense oligonucleotides; MicroRNAs
  • Mechanism of Action MicroRNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autosomal dominant polycystic kidney disease

Most Recent Events

  • 20 Dec 2017 Phase-I clinical trials in Autosomal-dominant polycystic kidney disease (In volunteers) in USA (SC)
  • 07 Nov 2017 Regulus files an IND application with the US FDA for Autosomal-dominant polycystic kidney disease before November 2017
  • 02 Mar 2017 Regulus Therapeutics announces intention to submit IND to US FDA for Autosomal-dominant polycystic kidney disease by end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top